查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1107873

短腸症候群的全球市場(2022年～2029年)

Global Short Bowel Syndrome Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球短腸症候群的市場規模在預測期間(2022年～2029年)預計將以15.9％的年複合成長率增長。

本報告提供全球短腸症候群市場相關調查分析，提供市場動態，產業分析，市場分析，競爭情形等系統性資訊。

目錄

第1章 全球短腸症候群的調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球短腸症候群市場-市場定義和概要

第3章 全球短腸症候群市場-摘要整理

  • 市場明細:各類藥物
  • 市場明細:各流通管道
  • 市場明細:各地區

第4章 全球短腸症候群市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 由於腸外營養成本高，對短腸綜合徵藥物的需求上升
  • 阻礙因素
    • 高額的治療費
  • 市場機會
  • 影響分析

第5章 全球短腸症候群市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 專利分析

第6章 全球短腸症候群市場上COVID-19分析

  • 市場上COVID-19分析
    • COVID-19前的市場方案
    • 目前COVID-19市場方案
    • COVID-19後或未來方案
  • 在COVID-19中的價格動態
  • 供需頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球短腸症候群市場:各類藥物

  • 簡介
    • 市場規模分析與與前一年同期比較成長率分析(%):各類藥物
    • 市場魅力指數:各類藥物
  • GLP-2*
    • 簡介
    • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
  • 生長激素
  • 麩醯胺酸
  • 其他

第8章 全球短腸症候群市場:各流通管道

  • 簡介
    • 市場規模分析與與前一年同期比較成長率分析(%):各流通管道
    • 市場魅力指數:各流通管道
  • 醫院藥局*
    • 簡介
    • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年)
  • 零售藥局
  • 其他

第9章 全球短腸症候群市場:各地區

  • 簡介
    • 市場規模分析，100萬美元(2020年～2029年)，及與前一年同期比較成長分析(%)(2021年～2029年):各地區
    • 市場魅力指數:各地區
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東和非洲

第10章 全球短腸症候群市場-競爭情形

  • 競爭模式
  • 主要的開發與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業
  • 顛覆性技術的企業

第11章 全球短腸症候群市場-企業簡介概要

  • Takeda Pharmaceutical Company Limited*
  • OxThera Inc
  • VectivBio AG
  • Nutrinia
  • Merck KGaA
  • Pfizer Inc
  • Ardelyx
  • Zealand Pharma
  • Nestle S.A

第12章 全球短腸症候群市場-DataM

  • 附錄
  • 關於本公司·服務
  • 諮詢方式
簡介目錄
Product Code: DMPH5626

Market Overview

Short bowel syndrome market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 15.9 % during the forecast period (2022-2029).

Short bowel syndrome (SBS) is a metabolic disorder that occurs due to the malfunctioning or removal of the small intestine through surgery due to digestive illness. The consequences may be malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.

Market Dynamics

The growth of the short bowel syndrome market is due to rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohn's disease (CD), which predisposes patients to development of SBS and mesenteric ischemia are the most common causes for SBS among all the age groups which demand the necessity of the treatment and high cost of parenteral nutrition increases demand for SBS drugs.

High cost of parenteral nutrition increases demand for SBS drugs is expected to hold the largest share in this market segment

Most of the short bowel syndrome patients are on parenteral nutrition initially until the patients' intestine has adopted and hemostasis is being maintained. The cost of parenteral nutrition varies from patient to patient, and ranges between US$ 150,000 and US$ 586,000 per year. High cost of parenteral nutrition increases the demand for short bowel syndrome drugs, which have shown the ability to reduce patient's dependence on parenteral nutrition during clinical trials.

For instance, Feb. 3, 2021, VectivBio Holding AG, apraglutide has the potential to enable patients to minimize the burden from parenteral support by increasing intestinal absorption of fluids, calories, and nutrients. The phase 3 STARS (STudy of ApRaglutide in SBS) trial is a global clinical trial that represents the largest phase 3 trial ever conducted in short bowel syndrome with intestinal failure (SBS-IF). STARS is the first trial of a next-generation, long-acting GLP-2 analog, designed to exclusively evaluate a once-weekly dosing interval and to take into account remnant bowel anatomy and individual caloric needs during weaning patients off of parenteral support.

High cost of treatment is likely to hamper the market growth

The cost of treatment of rare diseases is significantly high, which makes the treatment unaffordable for low-income groups. Additionally, lack of reimbursement in certain countries renders the treatment unreachable to several target group people.

For instance, in May 2019, the U.S. Food and Drug Administration (FDA) approved extending the indication of GITEX (teduglutide) for injection to pediatric patients 1 year of age and older with short bowel syndrome (SBS). Gattex (teduglutide) is an injectable drug used to treat adults with short bowel syndrome (SBS). Gattex is quite expensive, with treatment costing over US$ 295,000 a year. The cost of treatment for the lifetime renders the treatment unaffordable, as rare diseases are life-threatening and do not have a permanent cure, thereby leading to a decline in the number of patients preferring to avail the treatment.

COVID-19 Impact Analysis

Since patients with COVID-19 have reported gastrointestinal symptoms, such findings are creating additional revenue opportunities for manufacturers in the short bowel syndrome market. However, the SBS treatment requires long-term parenteral nutrition or an organ transplant. Hence, companies should collaborate with researchers to increase the study in autologous tissue engineering, which helps in treating an individual using their own cells or tissues. Companies are boosting their output capacities in anti-secretin agents to help patients reduce gastric acid in the intestine, growth hormones, and hypomotility agents to increase the time it takes the food to travel through intestines, resulting in increased nutrient absorption.

Segment Analysis

The GLP-2 drug therapy segment is expected to hold the largest share in this market segment

The GLP-2 drug treatment accounts for the major market share throughout the forecast period. The dominance is due to the only products available for treatment with the brand names Gattex and Revestive, introduced by Takeda which were approved for sales in both the US and Europe respectively. Also, the patent exclusivity of GLP-2 drug is anticipated to contribute to its significant share in the revenue of the global short bowel syndrome market.

For instance, Takeda Pharmaceuticals, on May 2019, announced that the US FDA approved extending the indication of GATTEX (teduglutide) for injection to pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding (parenteral support).

Geographical Analysis

North America region holds the largest market share of global short bowel syndrome market

North America is expected to major share of overall Short Bowel Syndrome Market throughout the forecast period. This dominance is mainly due to the revenue generated by the Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S. Also, rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders are a major factor that drives the market growth in the region.

Competitive Landscape

The global short bowel syndrome market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Takeda Pharmaceutical Company Limited, OxThera Inc, VectivBio AG, Nutrinia, Merck KGaA, Pfizer Inc, Ardelyx, Zealand Pharma and Nestle S.A. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the short bowel syndrome globally. For instance, In December 2020, 9 Meters Biopharma, Inc. announced positive topline results from its open-label phase 1b/2a clinical trial evaluating NM-002, its proprietary long-acting glucagon-like peptide-1 (GLP-1) receptor agonist in adults with short bowel syndrome (SBS). NM-002 is designed as a long-acting injectable GLP-1 receptor agonist that utilizes proprietary XTEN technology to extend circulating half-life. This is designed specifically to slow digestive transit time in SBS patients by reducing upper GI motility and improve the chronic diarrhea associated with a shortened intestine.

Key Companies to Watch

Takeda Pharmaceutical Company Limited

Overview: The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.

Product Portfolio: GATTEX (teduglutide) for subcutaneous injection is a prescription medicine used in adults and children 1 year of age and older with Short Bowel Syndrome (SBS).

Why Purchase the Report?

  • Visualize the composition of the short bowel syndrome market segmentation by drug class, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in short bowel syndrome market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of short bowel syndrome market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players.

The global short bowel syndrome market report would provide an access to an approx. 47 market data table, 41 figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Short Bowel Syndrome Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Short Bowel Syndrome Market - Market Definition and Overview

3. Global Short Bowel Syndrome Market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Global Short Bowel Syndrome Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
    • 4.1.2. High cost of parenteral nutrition increases demand for SBS drugs
  • 4.2. Restraints:
    • 4.2.1. High cost of treatment
  • 4.3. Opportunity
  • 4.4. Impact Analysis

5. Global Short Bowel Syndrome Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis

6. Global Short Bowel Syndrome Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Short Bowel Syndrome Market - By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. GLP-2*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Growth Hormone
  • 7.4. Glutamine
  • 7.5. Others

8. Global Short Bowel Syndrome Market - By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Retail Pharmacies
  • 8.4. Others

9. Global Short Bowel Syndrome Market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Global Short Bowel Syndrome Market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Key Developments and Strategies
  • 10.3. Company Share Analysis
  • 10.4. Product Benchmarking
  • 10.5. Key Companies to Watch
  • 10.6. Company with disruptive technology

11. Global Short Bowel Syndrome Market- Company Profiles

  • 11.1. Takeda Pharmaceutical Company Limited*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. OxThera Inc
  • 11.3. VectivBio AG
  • 11.4. Nutrinia
  • 11.5. Merck KGaA
  • 11.6. Pfizer Inc
  • 11.7. Ardelyx
  • 11.8. Zealand Pharma
  • 11.9. Nestle S.A

LIST NOT EXHAUSTIVE

12. Global Short Bowel Syndrome Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us